CORDIS
EU research results

CORDIS

English EN

Recombinant measles virus as a vector for HIV vaccines

Project information

Grant agreement ID: 19043

  • Start date

    1 January 2006

  • End date

    31 May 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 6 525 175

  • EU contribution

    € 5 499 324

Coordinated by:

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium

Objective

Twenty years after the discovery of human immunodeficiency virus (HIV)as the causative agent of the acquired immune deficiency syndrome (AIDS) a vaccine to prevent virus infection or mitigate disease is still not available. Accumulating data suggest that CD8-positive T cells play an important role in the control of HIV in the infected host. Therefore, several vaccine strategies based on DNA or recombinant viral or bacterial vectors have been devised to induce this type of immune response, and some of th ese vaccines are in early clinical testing. This proposal aims at demonstrating the safety and immunogenicity in humans of a novel recombinant measles virus (MV) vector for use as an AIDS vaccine. The vector is replication competent in vivo and is deriv ed from a widely used measles vaccine strain (Schwarz), which is known to induce very long lasting immunity. Therefore, this novel vector potentially offers a unique combination of safety and potency. The recombinant HIV MV vectors will express three re latively conserved HIV proteins (Gag, Pol, Nef) from HIV clade B and A strains. A good manufacturing practices (GMP) compatible production process for the recombinant MV vector will be developed and a GMP lot will be produced for two clinical studies. Th e first study will evaluate the safety profile of the MV vector, while the second study will assess in addition the immunogenicity in MV-immune volunteers. With these two clinical studies, the project will specifically address potential shedding of the r ecombinant vector into the environment and the potential negative impact of pre-existing MV immunity. It is expected that at the end of the project sufficient clinical data on the safety and immunogenicity will have been generated to decide on subsequent advanced technical and clinical development of this novel vaccine approach.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

GLAXOSMITHKLINE BIOLOGICALS SA

Address

Rue De L'Institut 89
--- Rixensart

Belgium

Participants (5)

INSTITUT PASTEUR

France

UNIVERSITEIT GENT

Belgium

ST. GEORGE'S - UNIVERSITY OF LONDON (PREV.: ST. GEORGE'S HOSPITAL MEDICAL SCHOOL)

United Kingdom

THE HEALTH PROTECTION AGENCY

United Kingdom

ASSITANCE PUBLIQUE - HÔPITAUX DE PARIS - CIC COCHIN

France

Project information

Grant agreement ID: 19043

  • Start date

    1 January 2006

  • End date

    31 May 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 6 525 175

  • EU contribution

    € 5 499 324

Coordinated by:

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium